Dld Asset Management, LP Intercept Pharmaceuticals, Inc. Put Options Transaction History

Dld Asset Management, LP

14 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2022 Aug 12, 2022	BUY	$11.23 - $19.59 $112,300 - $195,900	10,000 New	10,000 $138,000
Q1 2022 May 13, 2022	SELL	$13.37 - $17.79 $3.34 Million - $4.45 Million	-250,000 Closed	0 $0
Q4 2021 Feb 22, 2022	SELL	$14.28 - $19.53 $353 Million - $483 Million	-24,750,000 Reduced 99.0%	250,000 $4.07 Million
Q4 2021 Feb 14, 2022	BUY	$14.28 - $19.53 $354 Million - $484 Million	24,774,800 Added 11001.24%	25,000,000 $4.07 Million
Q3 2021 Nov 12, 2021	BUY	$12.99 - $20.47 $2.93 Million - $4.61 Million	225,200 New	225,200 $3.35 Million
Q3 2020 Nov 12, 2020	SELL	$39.09 - $53.44 $2.54 Million - $3.47 Million	-65,000 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$46.7 - $92.04 $84,060 - $165,672	1,800 Added 2.85%	65,000 $3.11 Million
Q1 2020 May 14, 2020	BUY	$48.35 - $118.68 $3.06 Million - $7.5 Million	63,200 New	63,200 $3.97 Million
Q3 2019 Nov 12, 2019	SELL	$58.69 - $80.46 $880,350 - $1.21 Million	-15,000 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$77.77 - $120.68 $112 Million - $173 Million	-1,434,900 Reduced 98.97%	15,000 $1.19 Million
Q1 2019 May 14, 2019	BUY	$91.83 - $120.68 $56.5 Million - $74.3 Million	615,300 Added 73.72%	1,449,900 $162 Million
Q4 2018 Feb 13, 2019	BUY	$85.79 - $126.46 $29.3 Million - $43.2 Million	341,600 Added 69.29%	834,600 $84.1 Million
Q3 2018 Nov 13, 2018	BUY	$88.49 - $127.55 $32.2 Million - $46.4 Million	364,000 Added 282.17%	493,000 $62.3 Million
Q2 2018 Aug 14, 2018	BUY	$60.0 - $85.67 $7.74 Million - $11.1 Million	129,000 New	129,000 $10.8 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Dld Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Dld Asset Management, LP with notifications on news.